BioProspect teams with US company in screening deal
23 January, 2003 by Melissa TrudingerQueensland-based BioProspect has formed a collaboration with US company Apath to screen BioProspect's natural plant extract library for potential antiviral therapeutics for hepatitis C virus (HCV) and other pathogenic viruses.
Leptin as a treatment for obesity? Fat chance
23 January, 2003 by Graeme O'NeillThe prospect of treating obese humans with leptin, a natural appetite suppressant secreted by fat cells, is looking increasingly slim after a new study by a Melbourne researcher.
Autogen says exercise affects genes for diabetes, obesity
22 January, 2003 by Melissa TrudingerShares in drug discovery company Autogen rose more than 15 per cent today after the company announced that nine new genes involved in diabetes and obesity were affected by exercise.
Gradipore cuts staff 15 per cent
22 January, 2003 by Pete YoungA 15 per cent staff cut at Sydney-based listed biotech Gradipore has been given an enthusiastic tick of approval by investors.
Progen boosts manufacturing arm with new US deal
21 January, 2003 by Pete YoungBrisbane biotech Progen Industries has reinforced the already significant contribution of its contract drug manufacturing arm by signing an agreement with US-based Sequella.
Researcher rues loss as marsupial genome opportunities hop overseas
20 January, 2003 by Graeme O'NeillA proposal for an Australian-based Kangaroo Genome Project has missed out on the latest round of Australian Research Council Research Centres of Excellence Grants, announced late last month.
GroPep back in the black
20 January, 2003 by Melissa TrudingerFulfilling a promise made to shareholders at its annual general meeting in November, Adelaide-based >GroPep has ended 2002 free of debt and with $AUD5.6 million cash in the bank, newly hired CFO Tony Mitchell said today.
Amrad to sell off its Melbourne HQ
17 January, 2003 by Melissa TrudingerDrug developer Amrad is to sell its 4.7 hectare campus in the prime inner city location of Richmond, in Melbourne.
Avax goes into liquidation
16 January, 2003 by Pete YoungCreditors of comatose Avax Group put the would-be cancer vaccine distributor into liquidation on Tuesday, making it the second biotech to exit the scene in as many months.
AustCancer gets commercialisation advice
16 January, 2003 by Graeme O'NeillPerth cancer therapeutic developer Australian Cancer Technology has engaged Intersuisse Corporate to advise it on a strategy for commercialising its Pentrix anti-cancer vaccine.
Norwood leaps to market as FDA approves device
16 January, 2003 by Melissa TrudingerNine months of waiting with bated breath ended this week when Norwood Abbey finally received approval from the US Food and Drug Administration to begin marketing its laser-assisted drug delivery device as a means to quickly and efficiently deliver local anaesthetic to the skin.
ResMed hires COO for North American subsidiary
14 January, 2003 by Graeme O'NeillSydney-based ResMed, manufacturer of world-leading devices for the diagnosis and treatment of sleep breathing disorders, has made a key appointment to its head its North American subsidiary, ResMed Corp.
Patent grant sees Novogen shares soar
14 January, 2003 by Melissa TrudingerNovogen's share price jumped more than 11 per cent to $3.81 yesterday after the company announced that an Australian patent had been granted for its topical skin repair treatment NV-07a.
Boron Molecular completes capital raising, considers IPO
10 January, 2003 by Melissa TrudingerBoron Molecular, a small Melbourne-based medicinal chemistry company, is planning to pursue listing on the Australian Stock Exchange in the next six months if market conditions are favourable, according to managing director Dr Phillip Reese.
Gene technology to be used in carp control plan
10 January, 2003 by Graeme O'NeillThe Murray-Darling Basin Commission is to back a radical new attempt to control Australia's worst aquatic pest, the carp.
